Congress approved an appropriations bill that makes FDA‑approved multi‑cancer early detection (MCED) tests eligible for Medicare reimbursement, a major policy shift for early‑detection diagnostics. The provision allows coverage for FDA‑cleared MCEDs at reimbursement levels tied to existing multi‑target stool DNA tests, phases in eligibility beginning with ages 50–65 in 2029, and raises the likelihood of commercial uptake by major diagnostics firms. The change circumvents current reliance on US Preventive Services Task Force endorsement for screening coverage, shortening a key barrier to Medicare access. Exact Sciences and other MCED developers publicly welcomed the move as a step toward broader patient access and predictable reimbursement. MCED tests use blood‑based or multi‑analyte assays to screen asymptomatic populations for multiple cancers; reimbursement policy directly affects market adoption, clinical deployment and payer economics. Stakeholders will monitor implementation details, coding, and pricing negotiations as the program is phased in. Key actors: US Congress, President (pending signature), Exact Sciences, MCED developers; reporting from financial and policy outlets.